EX937

Our Breakthrough Solution for Refractory Chronic Cough, a Serious Condition with No Current FDA-Approved Treatments

EX937, is a first-in-class, proprietary small molecule being developed for refractory chronic cough, a large underserved market with no current FDA-approved therapies, that affects approximately 10% of the global population. Leveraging a differentiated approach by inhibiting the FAAH enzyme, EX937 has demonstrated efficacy and favorable safety in its ability to modulate chronic cough in preclinical models.

Key EX937 Highlights

  • IND-enabling studies and pre-IND meeting completed
  • Once-a-day oral dosing
  • Potential for Fast Track Designation
  • Demonstrated efficacy and favorable safety by being entirely excluded from the central nervous system and brain
  • Conducting Phase 1 study in Australia provides numerus regulatory and financial benefits

Refractory Chronic Cough is a Significant Unmet Need with No FDA-Approved Drug

  1. Meltzer, E. O. (2021). Prevalence and Burden of Chronic Cough in the United States. The Journal of Allergy and Clinical Immunology, 9(11), 4037–4044.
  2. Lee JH et. al. Epidemiology of adult chronic cough: disease burden, regional issues, and recent findings. Asia Pac Allergy. 2021 Oct 18;11(4):e38. doi: 10.5415/apallergy.2021.11.e38. PMID: 34786368; PMCID: PMC8563099.
  3. Source: Transparency Market Research

Modulating Chronic Cough

Targeting FAAH Increases the Levels of Anandamide in Lung Tissue of the Guinea Pig Chronic Cough Model

  1. Worley et al. (2017). European Respiratory Journal, 50: 1700782
  2. Unpublished data from large pharma partner

 

Demonstrated Efficacy

Using Capsaicin, a potent compound found in chili peppers, to induce cough, EX937 is effectively able to reduce the number of coughs in guinea pig cough models at a dose of 10 mg/kg

  1. Meltzer, E. O. (2021). Prevalence and Burden of Chronic Cough in the United States. The Journal of Allergy and Clinical Immunology, 9(11), 4037–4044.
  2. Lee JH et. al. Epidemiology of adult chronic cough: disease burden, regional issues, and recent findings. Asia Pac Allergy. 2021 Oct 18;11(4):e38. doi: 10.5415/apallergy.2021.11.e38. PMID: 34786368; PMCID: PMC8563099.
  3. Source: Transparency Market Research

 

Key Scientific EX937 Publications

A list of published, peer-reviewed EX937 studies, including work from international, academic research laboratories, can be found here.

For more information, please contact us.